From:  Pharmacological potential of apigenin: a dietary flavonoid with emerging synergistic interactions in therapeutics

 Summary of apigenin’s biological effects observed in vitro, in vivo, and clinical studies, highlighting key outcomes, mechanisms, and translational relevance.

Methods Typical experimental system/dose rangesMain effects observedPutative mechanismsStrength
In vitro (cells, biochemical assays) [60]Cancer /immune/neuronal/endothelial cell lines; typical concentrations ~1–100 µM (commonly 5–50 µM)
  • Dose-dependent cytotoxicity against cancer cells, apoptosis, and cell-cycle arrest.

  • Anti-inflammatory (↓ NF-κB, ↓ pro-inflammatory cytokines). Antioxidant, anti-microbial, enzyme modulation (e.g., kinases).

Modulation of signalling (PI3K/Akt, MAPK, NF-κB), upregulation of pro-apoptotic proteins, inhibition of kinases and MMPs, and antioxidant enzyme activation.Strong, consistent mechanistic data across many cell types, but limited to controlled cell conditions (not directly predictive of human dosing).
In vivo (animal models) [61]Rodent disease models; doses often ~1–200 mg/kg (oral or i.p.) depending on model and duration
  • Tumor growth inhibition and metastasis suppression in several cancer models.

  • Anti-inflammatory and neuroprotective effects (improved functional outcomes in models).

  • Benefits in metabolic/cardiometabolic endpoints (improved insulin sensitivity, endothelial function), renal and hepatic protection in disease models.

Same pathways as in vitro plus effects on whole-organism pharmacology (reduced systemic cytokines, oxidative stress; improved organ histology). Often shows chemosensitization when combined with drugs.Good preclinical efficacy and safety signals, but results vary by formulation, dose, and model—translation to humans uncertain.
Clinical/human studies [62]Very limited controlled trials and PK studies; human trials mostly early-phase or pilot; clinicaltrials.gov lists PK/safety and small pilot studies
  • Pharmacokinetics/metabolism studied (bioavailability issues—rapid metabolism, glycoside forms differ).

  • A few small pilot studies investigate biomarker changes or feasibility (e.g., pilot studies in cancer risk groups).

  • No large, definitive RCT evidence of therapeutic efficacy for a specific disease yet.

Human metabolism (glucuronidation/sulfation) strongly affects exposure; formulations and glycoside forms change absorption.Insufficient clinical efficacy data. Safety in short studies appears acceptable, but robust efficacy and dosing regimens are not established—more human trials needed.